Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

Emily E Hartung, Kanwaldeep Singh, Sarah Coopersmith, Jamie Avrumutsoae, Siddaarth Varatharajan, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Ronan Foley, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2024) 144 (Supplement 1): 2764.

https://doi.org/10.1182/blood-2024-199648

Published: 2024

Journal Articles

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Naseer J Basma, Alexia J Strickson, Kristian Gurashi, Maria Kleppe, Hugh Young Rienhoff Jr., Jr., Tim CP Somervaille

Blood (2023) 142 (Supplement 1): 743.

https://doi.org/10.1182/blood-2023-181674

Published: 2023

Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood (2023) 142 (Supplement 1): 747.

https://doi.org/10.1182/blood-2023-179329

Published: 2023

Journal Articles

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

Yu Yan, Kanwaldeep Singh, Emily Hartung, Brendan Lee, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Brian Leber, Irwin Walker, Kylie L. Lepic, Maria Kleppe, Hugh Young Young Rienhoff Jr., Jr., Jonathan Bramson, Tobias Berg

Blood (2023) 142 (Supplement 1): 6793.

https://doi.org/10.1182/blood-2023-188472

Published: 2023

Journal Articles

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Blood (2023) 142 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2023-179569

Published: 2023

Journal Articles

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Kanwaldeep Singh, Emily Hartung, Christina Muhs, Islam Alshamleh, Monisha Divakaran, Anna Dvorkin-Gheva, Sara Pishyar, Pradhariny Prabagaran, Dina Khalaf, Alejandro Garcia-Horton, Stephen Ronan Foley, Brian Leber, Irwin Walker, Kylie Lepic, Harald Schwalbe, Hubert Serve, Maria Kleppe, Hugh Young Rienhoff, Jr., Tobias Berg

Blood (2023) 142 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2023-189515

Published: 2023

Journal Articles

Mutational Analysis of the Genome Stability Factor BOD1L1 in Myeloproliferative Neoplasm

Martin R Higgs, Sofia Browne, Ryan Collinson, Kathy Fuller, Wendy N. Erber, Maria Kleppe, Ben Sirnosian, Georges Natsoulis, Belinda Guo, Hugh Young Rienhoff Jr.

Blood (2023) 142 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2023-179125

Published: 2023

Journal Articles

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Blood (2023) 142 (1): 44–61.

https://doi.org/10.1182/blood.2022017230

Published: 2023

Includes: Supplemental data

Journal Articles

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Blood (2023) 141 (20): 2508–2519.

https://doi.org/10.1182/blood.2022015418

Published: 2023

Includes: Supplemental data

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic and Proteomic Profiling of AF10-Fusion Oncoproteins Reveal Mechanisms of Leukemogenesis and Actionable Targets

Bo-Rui Chen, PhD, Anagha Deshpande, PhD, Maria Kleppe, PhD, Narayana Yeddula, PhD, Sunnie Yoh, PhD, Scott A. Armstrong, MD PhD, Ross L. Levine, MD, Sumit Chanda, PhD, Aniruddha J. Deshpande, PhD

Blood (2018) 132 (Supplement 1): 544.

https://doi.org/10.1182/blood-2018-99-119210

Published: 2018

Journal Articles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Sara C. Meyer, MD PhD, Nilabh Ghosh, MSc, Simona Stivala, PhD, Anne Baerenwaldt, PhD, Hui Hao-Shen, Stefan Dirnhofer, MD, Matthias S. Dettmer, MD, Cédric Simillion, PhD, Sophia Chiu, MSc, Matthew Keller, MSc, Maria Kleppe, PhD, Morgane Hilpert, PhD, Andreas S. Buser, MD, Jakob R. Passweg, MDMS, Thomas Radimerski, PhD, Radek C. Skoda, MD, Ross L. Levine, MD

Blood (2017) 130 (Supplement 1): 381.

https://doi.org/10.1182/blood.V130.Suppl_1.381.381

Published: 2017

Journal Articles

Genomic Landscapes in Elderly AML

Blood (2017) 130 (Supplement 1): 404.

https://doi.org/10.1182/blood.V130.Suppl_1.404.404

Published: 2017

Journal Articles

JAK1 As a Convergent Regulator of Hematopoietic Stem Cell Function and Stress Hematopoiesis

Maria Kleppe, PhD, Matthew H Spitzer, PhD, Sheng Li, PhD, Lauren Dong, M.S., Efthymia Papalexi, Corinne Hill, M.S, Sofie De Groote, M.S., Matthew Keller, M.S., Priya Koppikar, PhD, Franck Rapaport, PhD, Jorge Gandara, Christopher E. Mason, PhD, Garry P. Nolan, Prof, PhD, Ross L. Levine, MD

Blood (2016) 128 (22): 722.

https://doi.org/10.1182/blood.V128.22.722.722

Published: 2016

Journal Articles

Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms

Maria Kleppe, PhD, Kaitlyn Shank, BS, Papalexi Efthymia, BS, Hugh Riehnhoff, MD, Ross L. Levine, MD

Blood (2015) 126 (23): 601.

https://doi.org/10.1182/blood.V126.23.601.601

Published: 2015

Journal Articles

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Blood (2015) 126 (22): 2479–2483.

https://doi.org/10.1182/blood-2015-03-635821

Published: 2015

Includes: Supplemental data

Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD

Blood (2014) 124 (21): 160.

https://doi.org/10.1182/blood.V124.21.160.160

Published: 2014

Journal Articles

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Sara C. Meyer, Matthew D. Keller, Brittany A. Woods, Lindsay M. LaFave, Lennart Bastian, Maria Kleppe, Neha Bhagwat, Sachie Marubayashi, Ross L. Levine

Blood (2014) 124 (14): 2280–2284.

https://doi.org/10.1182/blood-2014-03-560441

Published: 2014

Includes: Supplemental data

Journal Articles

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Neha Bhagwat, Priya Koppikar, Matthew Keller, Sachie Marubayashi, Kaitlyn Shank, Raajit Rampal, Jun Qi, Maria Kleppe, Hardik J. Patel, Smit K. Shah, Tony Taldone, James E. Bradner, Gabriela Chiosis, Ross L. Levine

Blood (2014) 123 (13): 2075–2083.

https://doi.org/10.1182/blood-2014-01-547760

Published: 2014

Includes: Supplemental data

Journal Articles

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

Michaël Porcu, Maria Kleppe, Valentina Gianfelici, Ellen Geerdens, Kim De Keersmaecker, Marco Tartaglia, Robin Foà, Jean Soulier, Barbara Cauwelier, Anne Uyttebroeck, Elizabeth Macintyre, Peter Vandenberghe, Vahid Asnafi, Jan Cools

Blood (2012) 119 (19): 4476–4479.

https://doi.org/10.1182/blood-2011-09-379958

Published: 2012

Includes: Supplemental data

NARROW

The Transcription Factor IRF8 Regulates the Sensitivity of AML Cells to LSD1 Inhibition and All-Trans Retinoic Acid

MSC Reprogramming and Aberrant Inflammatory Signaling in Myelofibrosis: Insights from Single-Cell RNA-Sequencing of Trephine Bone Marrow Cells

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

LSD1 Inhibition Enhances Antigen Presentation and Co-Stimulation in AML to Promote T Cell-Mediated Anti-Leukemia Immune Responses

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism

Mutational Analysis of the Genome Stability Factor BOD1L1 in Myeloproliferative Neoplasm

Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Genomic and Proteomic Profiling of AF10-Fusion Oncoproteins Reveal Mechanisms of Leukemogenesis and Actionable Targets

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Genomic Landscapes in Elderly AML

JAK1 As a Convergent Regulator of Hematopoietic Stem Cell Function and Stress Hematopoiesis

Lysine-Specific Histone Demethylase, LSD1, (KDM1A) As a Novel Therapeutic Target in Myeloproliferative Neoplasms

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only